InvestSMART

TrivarX Ltd (ASX:TRI)

ALERT: Price-sensitive ASX Announcement for TRI
Current share price for TRI : $0.023 -0.004 (-14.81%)+
Announcement
Release
22 Oct 2025 8:30AM
Price at Release
$0.027
Full Release
download
Summary
TrivarX Limited has announced the completion of patient recruitment for a US veteran-focused mental health trial, conducted in collaboration with the Greater Los Angeles Research and Education Foundation and the US Veterans Affairs Greater Los Angeles Healthcare System. The trial enrolled 60 patients and utilized TRI's single-channel ECG algorithm, designed to screen for current major depressive episodes and conduct sleep staging in veterans with suspected sleep apnea. This follows promising interim results from an initial cohort of 30 patients. The data gathered will undergo review, with full results expected later in the quarter, intended to support regulatory and commercial partnerships. The successful recruitment underlines the potential of the single-lead ECG algorithm as a scalable tool for mental health assessment.
Key Points
  • Patient recruitment for US veteran-focused mental health trial complete.
  • 60 patients enrolled using TRI's single-channel ECG algorithm.
  • Trial conducted with GLAVREF and US VA Greater Los Angeles Healthcare System.
  • Positive interim results reported from first 30 patients.
  • Full trial results expected later this quarter.
  • Commercial and regulatory engagement anticipated post-results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.